Sanofi Reports 1Q19 Orthobiologic Revenue of €68MM, Flat vs. 1Q18

Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.

U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18
Emerging markets were strong, with +15.4% revenue vs. last year


Synvisc and Synvisc-One sales on an as-reported basis are as follows...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us